A phase 3, multicenter, randomized, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with 131I-refractory differentiated thyroid cancer (SELECT)

Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Disclosures

Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Study Rationale

Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Study 303: Study Schema

Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Patient Characteristics

Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Primary Endpoint:<br />Kaplan-Meier Estimate of PFS

Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

PFS by Previous VEGF-Targeted Therapy

Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

PFS Subgroup Analyses

Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Response Rates

Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Best Tumor Response

Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Overall Survival, ITT population

Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Study Medication Exposure

Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Treatment-emergent Adverse Events (TEAEs)

Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Most Frequent Treatment-related Adverse Events (> 20%)

Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

TEAEs of Special Interest

Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Conclusions

Presented By Martin Schlumberger at 2014 ASCO Annual Meeting

Slide 17

Presented By Martin Schlumberger at 2014 ASCO Annual Meeting